Figure 1

Intrasplenic and intrapancreatic injections of adipose tissue-derived mesenchymal stem cells promote reversion of hyperglycemia in streptozotocin-induced diabetic mice. Adipose tissue-derived mesenchymal stem cells (ADMSCs; 1 × 10⁶) were administered by intrasplenic (n = 10) or intrapancreatic (n = 12) injection in diabetic mice 20 days after diabetes induction. Control groups were treated with injections of phosphate-buffered saline (Control-PBS, n = 5). Blood glucose levels (mg/dl) were frequently measured in nonfasting mice. (A) Intrasplenic ADMSC administration decreased blood glucose levels in 70% (7/10) of diabetic treated mice (responder: R-ADMSCs). (C) Intrapancreatic ADMSC injection reverted diabetes in 42% (5/12) of diabetic treated mice (R-ADMSCs). Nonresponder mice (NR-ADMSCs) remained hyperglycemic throughout the entire experimental period (glycemia >250 mg/dl). WT, wild-type/nondiabetic mice (n = 2). (B, D) Area under the curve (AUC) of glycemia from day 0 to day 70. The AUC was determined for each animal, and the average ± standard deviation of each group is shown. *P <0.05 (Control-PBS vs. R-ADMSCs), ^# P <0.05 (R-ADMSCs vs. NR-ADMSCs), &P <0.05 (WT vs. R-ADMSCs, for all evaluated time points).